{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:34:47Z","timestamp":1777599287806,"version":"3.51.4"},"reference-count":64,"publisher":"Bentham Science Publishers Ltd.","issue":"16","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772477"],"award-info":[{"award-number":["81772477"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,8,26]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most common\nmonogenic kidney disease, is caused by mutations in the PKD1, PKD2 or, in a very limited\nnumber of families, GANAB genes. Although cellular and molecular mechanisms of this disease\nhave been understood in the past 20 years, specific therapy approaches remain very little.\nBoth experimental and clinical studies show that the mammalian or mechanistic target of rapamycin\n(mTOR) pathway plays an important role during cyst formation and enlargement in\nADPKD. Studies in rodent models of ADPKD showed that mTOR inhibitors had a significant\nand long-lasting decrease in kidney volume and amelioration in kidney function. In the past\nover ten years, researchers have been devoting continuously to test mTOR inhibitors efficacy\nand safety in both preclinical studies and clinical trials in patients with ADPKD. In this review,\nwe will discuss the mTOR pathway thoroughly, mainly focusing on current advances in\nunderstanding its role in ADPKD, especially the recent progress of mTOR inhibitors use in\npreclinical studies and clinical trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867325666180330094434","type":"journal-article","created":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T08:02:27Z","timestamp":1522396947000},"page":"2962-2973","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open?"],"prefix":"10.2174","volume":"26","author":[{"given":"Pei","family":"Kou","sequence":"first","affiliation":[{"name":"Department of Nephrology, Wuhan No.1 Hospital, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of Health Ministry, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Wuhan No.1 Hospital, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","volume":"60","author":"Harris P.C.","year":"2009","unstructured":"Harris P.C.; Torres V.E.; Polycystic kidney disease. Annu Rev Med [http:\/\/dx.doi.org\/10.1146\/annurev.med.60.101707.125712]. [PMID: 18947299].2009,60,321-337","journal-title":"Annu Rev Med"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","volume":"76","author":"Torres V.E.","year":"2009","unstructured":"Torres V.E.; Harris P.C.; Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int [http:\/\/dx.doi.org\/10.1038\/ki.2009.128]. [PMID: 19455193].2009,76(2),149-168","journal-title":"Kidney Int"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrneph.2009.13","volume":"5","author":"Ecder T.","year":"2009","unstructured":"Ecder T.; Schrier R.W.; Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol [http:\/\/dx.doi.org\/10.1038\/nrneph.2009.13]. [PMID: 19322187].2009,5(4),221-228","journal-title":"Nat Rev Nephrol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00467-010-1656-1","volume":"26","author":"Sweeney W.E.","year":"2011","unstructured":"Sweeney W.E.; Avner E.D.; Diagnosis and management of childhood polycystic kidney disease. Pediatr Nephrol [http:\/\/dx.doi.org\/10.1007\/s00467-010-1656-1]. [PMID: 21046169].2011,26(5),675-692","journal-title":"Pediatr Nephrol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1590\/S0100-879X2006001200004","volume":"39","author":"Menezes L.F.","year":"2006","unstructured":"Menezes L.F.; Onuchic L.F.; Molecular and cellular pathogenesis of autosomal recessive polycystic kidney disease. Braz J Med Biol Res [http:\/\/dx.doi.org\/10.1590\/S0100-879X2006001200004]. [PMID: 17160262].2006,39(12),1537-1548","journal-title":"Braz J Med Biol Res"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1681\/ASN.2008050456","volume":"20","author":"Hildebrandt F.","year":"2009","unstructured":"Hildebrandt F.; Attanasio M.; Otto E.; Nephronophthisis: Disease mechanisms of a ciliopathy. J Am Soc Nephrol [http:\/\/dx.doi.org\/10.1681\/ASN.2008050456]. [PMID: 19118152].2009,20(1),23-35","journal-title":"J Am Soc Nephrol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molmed.2011.06.003","volume":"17","author":"Ibraghimov-Beskrovnaya O.","year":"2011","unstructured":"Ibraghimov-Beskrovnaya O.; Natoli T.A.; mTOR signaling in polycystic kidney disease. Trends Mol Med [http:\/\/dx.doi.org\/10.1016\/j.molmed.2011.06.003]. [PMID: 21775207].2011,17(11),625-633","journal-title":"Trends Mol Med"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3949\/ccjm.76a.gr001","volume":"76","author":"Braun W.E.","year":"2009","unstructured":"Braun W.E.; Autosomal dominant polycystic kidney disease: emerging concepts of pathogenesis and new treatments. Cleve Clin J Med [http:\/\/dx.doi.org\/10.3949\/ccjm.76a.gr001]. [PMID: 19188475].2009,76(2),97-104","journal-title":"Cleve Clin J Med"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.krcp.2012.07.002","volume":"31","author":"Kim H.J.","year":"2012","unstructured":"Kim H.J.; Edelstein C.L.; Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside. Kidney Res Clin Pract [http:\/\/dx.doi.org\/10.1016\/j.krcp.2012.07.002]. [PMID: 26894018].2012,31(3),132-138","journal-title":"Kidney Res Clin Pract"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM199307293290508","volume":"329","author":"Gabow P.A.","year":"1993","unstructured":"Gabow P.A.; Autosomal dominant polycystic kidney disease. N Engl J Med [http:\/\/dx.doi.org\/10.1056\/NEJM199307293290508]. [PMID: 8321262].1993,329(5),332-342","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.ackd.2010.01.006","volume":"17","author":"Torres V.E.","year":"2010","unstructured":"Torres V.E.; Treatment strategies and clinical trial design in ADPKD. Adv Chronic Kidney Dis [http:\/\/dx.doi.org\/10.1053\/j.ackd.2010.01.006]. [PMID: 20219622].2010,17(2),190-204","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"Torres V.E.","year":"2007","unstructured":"Torres V.E.; Harris P.C.; Pirson Y.; Autosomal dominant polycystic kidney disease. Lancet [http:\/\/dx.doi.org\/10.1016\/S0140-6736(07)60601-1]. [PMID: 17434405].2007,369(9569),1287-1301","journal-title":"Lancet"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev.biochem.75.103004.142819","volume":"76","author":"Venkatachalam K.","year":"2007","unstructured":"Venkatachalam K.; Montell C.; TRP channels. Annu Rev Biochem [http:\/\/dx.doi.org\/10.1146\/annurev.biochem.75.103004.142819]. [PMID: 17579562].2007,76,387-417","journal-title":"Annu Rev Biochem"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","volume":"98","author":"Porath B.","year":"2016","unstructured":"Porath B.; Gainullin V.G.; Cornec-Le Gall E.; Dillinger E.K.; Heyer C.M.; Hopp K.; Edwards M.E.; Madsen C.D.; Mauritz S.R.; Banks C.J.; Baheti S.; Reddy B.; Herrero J.I.; Ba\u00f1ales J.M.; Hogan M.C.; Tasic V.; Watnick T.J.; Chapman A.B.; Vigneau C.; Lavainne F.; Audr\u00e9zet M.P.; Ferec C.; Le Meur Y.; Torres V.E.; Harris P.C.; Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet [http:\/\/dx.doi.org\/10.1016\/j.ajhg.2016.05.004]. [PMID: 27259053].2016,98(6),1193-1207","journal-title":"Am J Hum Genet"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ng1294-328","volume":"8","author":"Brook-Carter P.T.","year":"1994","unstructured":"Brook-Carter P.T.; Peral B.; Ward C.J.; Thompson P.; Hughes J.; Maheshwar M.M.; Nellist M.; Gamble V.; Harris P.C.; Sampson J.R.; Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease-a contiguous gene syndrome. Nat Genet [http:\/\/dx.doi.org\/10.1038\/ng1294-328]. [PMID: 7894481].1994,8(4),328-332","journal-title":"Nat Genet"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1101\/gad.887201","volume":"15","author":"Gingras A.C.","year":"2001","unstructured":"Gingras A.C.; Raught B.; Sonenberg N.; Regulation of translation initiation by FRAP\/mTOR. Genes Dev [http:\/\/dx.doi.org\/10.1101\/gad.887201]. [PMID: 11297505].2001,15(7),807-826","journal-title":"Genes Dev"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.molcel.2010.05.017","volume":"38","author":"Yip C.K.","year":"2010","unstructured":"Yip C.K.; Murata K.; Walz T.; Sabatini D.M.; Kang S.A.; Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell [http:\/\/dx.doi.org\/10.1016\/j.molcel.2010.05.017]. [PMID: 20542007].2010,38(5),768-774","journal-title":"Mol Cell"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","volume":"137","author":"Peterson T.R.","year":"2009","unstructured":"Peterson T.R.; Laplante M.; Thoreen C.C.; Sancak Y.; Kang S.A.; Kuehl W.M.; Gray N.S.; Sabatini D.M.; DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell [http:\/\/dx.doi.org\/10.1016\/j.cell.2009.03.046]. [PMID: 19446321].2009,137(5),873-886","journal-title":"Cell"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","volume":"6","author":"Jacinto E.","year":"2004","unstructured":"Jacinto E.; Loewith R.; Schmidt A.; Lin S.; R\u00fcegg M.A.; Hall A.; Hall M.N.; Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol [http:\/\/dx.doi.org\/10.1038\/ncb1183]. [PMID: 15467718].2004,6(11),1122-1128","journal-title":"Nat Cell Biol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","volume":"14","author":"Sarbassov D.D.","year":"2004","unstructured":"Sarbassov D.D.; Ali S.M.; Kim D.H.; Guertin D.A.; Latek R.R.; Erdjument-Bromage H.; Tempst P.; Sabatini D.M.; Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol [http:\/\/dx.doi.org\/10.1016\/j.cub.2004.06.054]. [PMID: 15268862].2004,14(14),1296-1302","journal-title":"Curr Biol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"Wullschleger S.","year":"2006","unstructured":"Wullschleger S.; Loewith R.; Hall M.N.; TOR signaling in growth and metabolism. Cell [http:\/\/dx.doi.org\/10.1016\/j.cell.2006.01.016]. [PMID: 16469695].2006,124(3),471-484","journal-title":"Cell"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","volume":"110","author":"Kim D.H.","year":"2002","unstructured":"Kim D.H.; Sarbassov D.D.; Ali S.M.; King J.E.; Latek R.R.; Erdjument-Bromage H.; Tempst P.; Sabatini D.M.; mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell [http:\/\/dx.doi.org\/10.1016\/S0092-8674(02)00808-5]. [PMID: 12150925].2002,110(2),163-175","journal-title":"Cell"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"Sarbassov D.D.","year":"2005","unstructured":"Sarbassov D.D.; Guertin D.A.; Ali S.M.; Sabatini D.M.; Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science [http:\/\/dx.doi.org\/10.1126\/science.1106148]. [PMID: 15718470].2005,307(5712),1098-1101","journal-title":"Science"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrneph.2016.108","volume":"12","author":"Fantus D.","year":"2016","unstructured":"Fantus D.; Rogers N.M.; Grahammer F.; Huber T.B.; Thomson A.W.; Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat Rev Nephrol [http:\/\/dx.doi.org\/10.1038\/nrneph.2016.108]. [PMID: 27477490].2016,12(10),587-609","journal-title":"Nat Rev Nephrol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/hmg\/ddp149","volume":"18","author":"Bonnet C.S.","year":"2009","unstructured":"Bonnet C.S.; Aldred M.; von Ruhland C.; Harris R.; Sandford R.; Cheadle J.P.; Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Hum Mol Genet [http:\/\/dx.doi.org\/10.1093\/hmg\/ddp149]. [PMID: 19321600].2009,18(12),2166-2176","journal-title":"Hum Mol Genet"},{"key":"ref=26","first-page":"S119","volume":"2","author":"Cai S.L.","year":"2006","unstructured":"Cai S.L.; Walker C.L.; TSC2, a key player in tumor suppression and cystic kidney disease. Nephrol Ther [PMID: 17373211].2006,2(Suppl. 2),S119-S122","journal-title":"Nephrol Ther"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1097-2765(01)00226-X","volume":"7","author":"Kleymenova E.","year":"2001","unstructured":"Kleymenova E.; Ibraghimov-Beskrovnaya O.; Kugoh H.; Everitt J.; Xu H.; Kiguchi K.; Landes G.; Harris P.; Walker C.; Tuberin-dependent membrane localization of polycystin-1: A functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell [http:\/\/dx.doi.org\/10.1016\/S1097-2765(01)00226-X]. [PMID: 11336705].2001,7(4),823-832","journal-title":"Mol Cell"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","volume":"10","author":"Canaud G.","year":"2010","unstructured":"Canaud G.; Knebelmann B.; Harris P.C.; Vrtovsnik F.; Correas J.M.; Pallet N.; Heyer C.M.; Letavernier E.; Bienaim\u00e9 F.; Thervet E.; Martinez F.; Terzi F.; Legendre C.; Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? Am J Transplant [http:\/\/dx.doi.org\/10.1111\/j.1600-6143.2010.03152.x]. [PMID: 20642692].2010,10(7),1701-1706","journal-title":"Am J Transplant"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","volume":"103","author":"Shillingford J.M.","year":"2006","unstructured":"Shillingford J.M.; Murcia N.S.; Larson C.H.; Low S.H.; Hedgepeth R.; Brown N.; Flask C.A.; Novick A.C.; Goldfarb D.A.; Kramer-Zucker A.; Walz G.; Piontek K.B.; Germino G.G.; Weimbs T.; The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA [http:\/\/dx.doi.org\/10.1073\/pnas.0509694103]. [PMID: 16567633].2006,103(14),5466-5471","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/ki.2010.250","volume":"78","author":"Zafar I.","year":"2010","unstructured":"Zafar I.; Ravichandran K.; Belibi F.A.; Doctor R.B.; Edelstein C.L.; Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int [http:\/\/dx.doi.org\/10.1038\/ki.2010.250]. [PMID: 20686448].2010,78(8),754-761","journal-title":"Kidney Int"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ki.2009.147","volume":"76","author":"Gattone V.H.","year":"2009","unstructured":"Gattone V.H.; Sinders R.M.; Hornberger T.A.; Robling A.G.; Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. Kidney Int [http:\/\/dx.doi.org\/10.1038\/ki.2009.147]. [PMID: 19421190].2009,76(2),178-182","journal-title":"Kidney Int"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nm.2171","volume":"16","author":"Natoli T.A.","year":"2010","unstructured":"Natoli T.A.; Smith L.A.; Rogers K.A.; Wang B.; Komarnitsky S.; Budman Y.; Belenky A.; Bukanov N.O.; Dackowski W.R.; Husson H.; Russo R.J.; Shayman J.A.; Ledbetter S.R.; Leonard J.P.; Ibraghimov-Beskrovnaya O.; Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med [http:\/\/dx.doi.org\/10.1038\/nm.2171]. [PMID: 20562878].2010,16(7),788-792","journal-title":"Nat Med"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/hmg\/ddn325","volume":"18","author":"Hartman T.R.","year":"2009","unstructured":"Hartman T.R.; Liu D.; Zilfou J.T.; Robb V.; Morrison T.; Watnick T.; Henske E.P.; The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum Mol Genet [http:\/\/dx.doi.org\/10.1093\/hmg\/ddn325]. [PMID: 18845692].2009,18(1),151-163","journal-title":"Hum Mol Genet"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4161\/cc.8.7.8044","volume":"8","author":"Foster D.A.","year":"2009","unstructured":"Foster D.A.; Toschi A.; Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle [http:\/\/dx.doi.org\/10.4161\/cc.8.7.8044]. [PMID: 19270529].2009,8(7),1026-1029","journal-title":"Cell Cycle"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/jmg.33.6.480","volume":"33","author":"Cook J.A.","year":"1996","unstructured":"Cook J.A.; Oliver K.; Mueller R.F.; Sampson J.; A cross sectional study of renal involvement in tuberous sclerosis. J Med Genet [http:\/\/dx.doi.org\/10.1136\/jmg.33.6.480]. [PMID: 8782048].1996,33(6),480-484","journal-title":"J Med Genet"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","volume":"10","author":"Benjamin D.","year":"2011","unstructured":"Benjamin D.; Colombi M.; Moroni C.; Hall M.N.; Rapamycin passes the torch: A new generation of mTOR inhibitors. Nat Rev Drug Discov [http:\/\/dx.doi.org\/10.1038\/nrd3531]. [PMID: 22037041].2011,10(11),868-880","journal-title":"Nat Rev Drug Discov"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5","author":"Faivre S.","year":"2006","unstructured":"Faivre S.; Kroemer G.; Raymond E.; Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov [http:\/\/dx.doi.org\/10.1038\/nrd2062]. [PMID: 16883305].2006,5(8),671-688","journal-title":"Nat Rev Drug Discov"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1128\/MCB.00782-08","volume":"29","author":"Toschi A.","year":"2009","unstructured":"Toschi A.; Lee E.; Xu L.; Garcia A.; Gadir N.; Foster D.A.; Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: Competition with rapamycin. Mol Cell Biol [http:\/\/dx.doi.org\/10.1128\/MCB.00782-08]. [PMID: 19114562].2009,29(6),1411-1420","journal-title":"Mol Cell Biol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","volume":"21","author":"Shillingford J.M.","year":"2010","unstructured":"Shillingford J.M.; Piontek K.B.; Germino G.G.; Weimbs T.; Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol [http:\/\/dx.doi.org\/10.1681\/ASN.2009040421]. [PMID: 20075061].2010,21(3),489-497","journal-title":"J Am Soc Nephrol"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10334-008-0158-7","volume":"22","author":"Reichardt W.","year":"2009","unstructured":"Reichardt W.; Romaker D.; Becker A.; Buechert M.; Walz G.; von Elverfeldt D.; Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD. MAGMA [http:\/\/dx.doi.org\/10.1007\/s10334-008-0158-7]. [PMID: 19107537].2009,22(3),143-149","journal-title":"MAGMA"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","volume":"16","author":"Tao Y.","year":"2005","unstructured":"Tao Y.; Kim J.; Schrier R.W.; Edelstein C.L.; Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol [http:\/\/dx.doi.org\/10.1681\/ASN.2004080660]. [PMID: 15563559].2005,16(1),46-51","journal-title":"J Am Soc Nephrol"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","volume":"21","author":"Wahl P.R.","year":"2006","unstructured":"Wahl P.R.; Serra A.L.; Le Hir M.; Molle K.D.; Hall M.N.; W\u00fcthrich R.P.; Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Nephrol Dial Transplant [http:\/\/dx.doi.org\/10.1093\/ndt\/gfi181]. [PMID: 16221708].2006,21(3),598-604","journal-title":"Nephrol Dial Transplant"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ndt\/gfq384","volume":"26","author":"Renken C.","year":"2011","unstructured":"Renken C.; Fischer D.C.; Kundt G.; Gretz N.; Haffner D.; Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. Nephrol Dial Transplant [http:\/\/dx.doi.org\/10.1093\/ndt\/gfq384]. [PMID: 20615907].2011,26(1),92-100","journal-title":"Nephrol Dial Transplant"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"F236","DOI":"10.1152\/ajprenal.00129.2010","volume":"300","author":"Belibi F.","year":"2011","unstructured":"Belibi F.; Ravichandran K.; Zafar I.; He Z.; Edelstein C.L.; mTORC1\/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. Am J Physiol Renal Physiol [http:\/\/dx.doi.org\/10.1152\/ajprenal.00129.2010]. [PMID: 20943770].2011,300(1),F236-F244","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"10786","DOI":"10.1038\/ncomms10786","volume":"7","author":"Pema M.","year":"2016","unstructured":"Pema M.; Drusian L.; Chiaravalli M.; Castelli M.; Yao Q.; Ricciardi S.; Somlo S.; Qian F.; Biffo S.; Boletta A.; mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex. Nat Commun [http:\/\/dx.doi.org\/10.1038\/ncomms10786]. [PMID: 26931735].2016,7,10786","journal-title":"Nat Commun"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"F1597","DOI":"10.1152\/ajprenal.00430.2009","volume":"297","author":"Wu M.","year":"2009","unstructured":"Wu M.; Arcaro A.; Varga Z.; Vogetseder A.; Le Hir M.; W\u00fcthrich R.P.; Serra A.L.; Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol [http:\/\/dx.doi.org\/10.1152\/ajprenal.00430.2009]. [PMID: 19776171].2009,297(6),F1597-F1605","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000104818","volume":"30","author":"Wu M.","year":"2007","unstructured":"Wu M.; Wahl P.R.; Le Hir M.; Wackerle-Men Y.; Wuthrich R.P.; Serra A.L.; Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res [http:\/\/dx.doi.org\/10.1159\/000104818]. [PMID: 17596700].2007,30(4),253-259","journal-title":"Kidney Blood Press Res"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"Grantham J.J.","year":"2006","unstructured":"Grantham J.J.; Torres V.E.; Chapman A.B.; Guay-Woodford L.M.; Bae K.T.; King B.F.; Wetzel L.H.; Baumgarten D.A.; Kenney P.J.; Harris P.C.; Klahr S.; Bennett W.M.; Hirschman G.N.; Meyers C.M.; Zhang X.; Zhu F.; Miller J.P.; Volume progression in polycystic kidney disease. N Engl J Med [http:\/\/dx.doi.org\/10.1056\/NEJMoa054341]. [PMID: 16707749].2006,354(20),2122-2130","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01360210","volume":"5","author":"Torres V.E.","year":"2010","unstructured":"Torres V.E.; Boletta A.; Chapman A.; Gattone V.; Pei Y.; Qian Q.; Wallace D.P.; Weimbs T.; W\u00fcthrich R.P.; Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol [http:\/\/dx.doi.org\/10.2215\/CJN.01360210]. [PMID: 20498248].2010,5(7),1312-1329","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","volume":"19","author":"Qian Q.","year":"2008","unstructured":"Qian Q.; Du H.; King B.F.; Kumar S.; Dean P.G.; Cosio F.G.; Torres V.E.; Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol [http:\/\/dx.doi.org\/10.1681\/ASN.2007050626]. [PMID: 18199797].2008,19(3),631-638","journal-title":"J Am Soc Nephrol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"Serra A.L.","year":"2010","unstructured":"Serra A.L.; Poster D.; Kistler A.D.; Krauer F.; Raina S.; Young J.; Rentsch K.M.; Spanaus K.S.; Senn O.; Kristanto P.; Scheffel H.; Weishaupt D.; W\u00fcthrich R.P.; Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med [http:\/\/dx.doi.org\/10.1056\/NEJMoa0907419]. [PMID: 20581391].2010,363(9),820-829","journal-title":"N Engl J Med"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"Walz G.","year":"2010","unstructured":"Walz G.; Budde K.; Mannaa M.; N\u00fcrnberger J.; Wanner C.; Sommerer C.; Kunzendorf U.; Banas B.; H\u00f6rl W.H.; Oberm\u00fcller N.; Arns W.; Pavenst\u00e4dt H.; Gaedeke J.; B\u00fcchert M.; May C.; Gschaidmeier H.; Kramer S.; Eckardt K.U.; Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med [http:\/\/dx.doi.org\/10.1056\/NEJMoa1003491]. [PMID: 20581392].2010,363(9),830-840","journal-title":"N Engl J Med"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/ki.2010.457","volume":"79","author":"Huber T.B.","year":"2011","unstructured":"Huber T.B.; Walz G.; Kuehn E.W.; mTOR and rapamycin in the kidney: Signaling and therapeutic implications beyond immunosuppression. Kidney Int [http:\/\/dx.doi.org\/10.1038\/ki.2010.457]. [PMID: 21085109].2011,79(5),502-511","journal-title":"Kidney Int"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","volume":"21","author":"Perico N.","year":"2010","unstructured":"Perico N.; Antiga L.; Caroli A.; Ruggenenti P.; Fasolini G.; Cafaro M.; Ondei P.; Rubis N.; Diadei O.; Gherardi G.; Prandini S.; Panozo A.; Bravo R.F.; Carminati S.; De Leon F.R.; Gaspari F.; Cortinovis M.; Motterlini N.; Ene-Iordache B.; Remuzzi A.; Remuzzi G.; Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol [http:\/\/dx.doi.org\/10.1681\/ASN.2009121302]. [PMID: 20466742].2010,21(6),1031-1040","journal-title":"J Am Soc Nephrol"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1093\/ndt\/gfq527","volume":"25","author":"Ponticelli C.","year":"2010","unstructured":"Ponticelli C.; Locatelli F.; Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment. Nephrol Dial Transplant [http:\/\/dx.doi.org\/10.1093\/ndt\/gfq527]. [PMID: 20798121].2010,25(12),3809-3812","journal-title":"Nephrol Dial Transplant"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4155\/fmc.10.233","volume":"2","author":"Roychowdhury A.","year":"2010","unstructured":"Roychowdhury A.; Sharma R.; Kumar S.; Recent advances in the discovery of small molecule mTOR inhibitors. Future Med Chem [http:\/\/dx.doi.org\/10.4155\/fmc.10.233]. [PMID: 21426150].2010,2(10),1577-1589","journal-title":"Future Med Chem"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/acschembio.6b00849","volume":"12","author":"Head S.A.","year":"2017","unstructured":"Head S.A.; Shi W.Q.; Yang E.J.; Nacev B.A.; Hong S.Y.; Pasunooti K.K.; Li R.J.; Shim J.S.; Liu J.O.; Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis. ACS Chem Biol [http:\/\/dx.doi.org\/10.1021\/acschembio.6b00849]. [PMID: 28103683].2017,12(1),174-182","journal-title":"ACS Chem Biol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.mehy.2009.05.043","volume":"73","author":"McCarty M.F.","year":"2009","unstructured":"McCarty M.F.; Barroso-Aranda J.; Contreras F.; Activation of AMP-activated kinase as a strategy for managing autosomal dominant polycystic kidney disease. Med Hypotheses [http:\/\/dx.doi.org\/10.1016\/j.mehy.2009.05.043]. [PMID: 19570618].2009,73(6),1008-1010","journal-title":"Med Hypotheses"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"Takiar V.","year":"2011","unstructured":"Takiar V.; Nishio S.; Seo-Mayer P.; King J.D.; Li H.; Zhang L.; Karihaloo A.; Hallows K.R.; Somlo S.; Caplan M.J.; Activating AMP-Activated Protein Kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA [http:\/\/dx.doi.org\/10.1073\/pnas.1011498108]. [PMID: 21262823].2011,108(6),2462-2467","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.09900915","volume":"11","author":"Ruggenenti P.","year":"2016","unstructured":"Ruggenenti P.; Gentile G.; Perico N.; Perna A.; Barcella L.; Trillini M.; Cortinovis M.; Ferrer Siles C.P.; Reyes Loaeza J.A.; Aparicio M.C.; Fasolini G.; Gaspari F.; Martinetti D.; Carrara F.; Rubis N.; Prandini S.; Caroli A.; Sharma K.; Antiga L.; Remuzzi A.; Remuzzi G.; Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4. Clin J Am Soc Nephrol [http:\/\/dx.doi.org\/10.2215\/CJN.09900915]. [PMID: 26912555].2016,11(5),785-794","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000354398","volume":"124","author":"Xue C.","year":"2013","unstructured":"Xue C.; Dai B.; Mei C.; Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis. Nephron Clin Pract [http:\/\/dx.doi.org\/10.1159\/000354398]. [PMID: 24022660].2013,124(1-2),10-16","journal-title":"Nephron Clin Pract"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1681\/ASN.2012040367","volume":"23","author":"Shillingford J.M.","year":"2012","unstructured":"Shillingford J.M.; Leamon C.P.; Vlahov I.R.; Weimbs T.; Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol [http:\/\/dx.doi.org\/10.1681\/ASN.2012040367]. [PMID: 22859856].2012,23(10),1674-1681","journal-title":"J Am Soc Nephrol"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13063-015-0692-3","volume":"16","author":"Riegersperger M.","year":"2015","unstructured":"Riegersperger M.; Herkner H.; Sunder-Plassmann G.; Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): Study protocol for a randomized controlled trial. Trials [http:\/\/dx.doi.org\/10.1186\/s13063-015-0692-3]. [PMID: 25899445].2015,16,182","journal-title":"Trials"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.02650313","volume":"9","author":"Braun W.E.","year":"2014","unstructured":"Braun W.E.; Schold J.D.; Stephany B.R.; Spirko R.A.; Herts B.R.; Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study. Clin J Am Soc Nephrol [http:\/\/dx.doi.org\/10.2215\/CJN.02650313]. [PMID: 24721888].2014,9(5),881-888","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/160858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T08:43:11Z","timestamp":1569832991000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/160858\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,26]]},"references-count":64,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,8,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867325666180330094434","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}